Acute Watery DiarrheaNCT07921836
Comparison of Two Probiotics for Reducing Diarrhea Frequency in Children Aged 6-24 Months
A study testing Saccharomyces boulardii CNCM I-745 and Bacillus clausii (O/C, SIN, N/R, T) in people with Acute Watery Diarrhea and Acute Watery Diarrhoea, run by King Edward Medical University.
Trial summary
Clinical Trial Summary The goal of this clinical trial is to compare the effectiveness of Saccharomyces boulardii CNCM I-745 and multi-strain Bacillus clausii in reducing the frequency of acute watery diarrhea in children aged 6 to 24 months. Read more about this study
- Who is it for?
- Ages 6 to 24 months
- Conditions the study is for
- Acute Watery Diarrhea, Acute Watery Diarrhoea, Diarrhea
- What is being tested?
- Saccharomyces boulardii CNCM I-745 and Bacillus clausii (O/C, SIN, N/R, T)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 88 participants
- Where
- No sites listed yet
- Study dates
- Nov 2026to Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 24 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Children aged 6 to 24 months.
- Children of either sex.
- Children with a clinical diagnosis of acute watery diarrhea, defined as three or more loose/liquid stools per day for less than 14 days, with some dehydration.
- Children able to take oral medication.
Who cannot join
- Children with severe systemic illness, including immunodeficiency, sepsis, or congenital gastrointestinal anomalies.
- Children with severe malnutrition.
- Children who received systemic antibiotics, probiotics, or medications affecting gastrointestinal motility, including laxatives, antiemetics, antisecretory agents, adsorbent medications, or opiates, within 7 days before enrollment.
- Children with a known allergy or hypersensitivity to either study probiotic or any of its formulation components.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Dr. Mimpal Singh Associate Professor, Paediatrics, MBBS, MCPS, MD, DCH, PHD, PGPN contact
About this study
Official title: Comparison of the Effectiveness of Saccharomyces Boulardii CNCM I-745 and Multi-Strain Bacillus Clausii in Reducing the Frequency of Acute Watery Diarrhea in Children Aged 6 to 24 Months
Clinical Trial Summary
The goal of this clinical trial is to compare the effectiveness of Saccharomyces boulardii CNCM I-745 and multi-strain Bacillus clausii in reducing the frequency of acute watery diarrhea in children aged 6 to 24 months. The main question it aims to answer is:
Read more
- Which probiotic is more effective in reducing the daily frequency of acute watery diarrhea in children?
Researchers will compare Saccharomyces boulardii CNCM I-745 with a four-strain mixture of Bacillus clausii (O/C, SIN, N/R, T) to determine which is more effective in reducing diarrhea frequency.
Participants will:
- Receive either Saccharomyces boulardii CNCM I-745 at a daily dose of 10 billion CFU or multi-strain Bacillus clausii at a daily dose of 4 billion CFU for 3 days.
- Receive standard treatment for diarrhea, including oral rehydration therapy (ORS), zinc supplementation, and dietary advice.
- Be followed for 3 days after admission, with daily recording of the frequency of diarrhea episodes.
Read the detailed description
- Background and Rationale
Acute watery diarrhea is an important cause of morbidity among children under five years of age, particularly in resource-limited settings. In young children, ongoing fluid loss can result in dehydration and may lead to serious complications if appropriate management is delayed. The mainstay of treatment is oral rehydration therapy (ORS), zinc supplementation, continued breastfeeding, and appropriate dietary management. Probiotics have also been used as adjuncts to standard treatment, with the aim of improving clinical recovery. However, the effectiveness of probiotics may vary according to the specific microorganism and strain used.
Saccharomyces boulardii CNCM I-745 is a yeast probiotic that has been investigated for its role in pediatric acute gastroenteritis. Bacillus clausii is a spore-forming bacterial probiotic, and the four strains O/C, SIN, N/R, and T have also been used in the management of gastrointestinal disorders, including diarrhea in children. Although both preparations have been studied individually, direct comparisons between these probiotic preparations in children with acute watery diarrhea remain limited.
Differences in their biological characteristics and the limited availability of direct comparative evidence provide a rationale for evaluating these two preparations within the same clinical setting and study population. Such a comparison may contribute to a better understanding of their relative effectiveness when used alongside standard treatment.
- Study Purpose
The purpose of this study is to compare the effectiveness of *Saccharomyces boulardii* CNCM I-745 and a four-strain preparation of *Bacillus clausii* (O/C, SIN, N/R, and T) in reducing the daily frequency of acute watery diarrhea in young children.
The study focuses on the change in the frequency of diarrhea episodes during the treatment and observation period. The comparison is intended to determine whether the two probiotic preparations differ in their effectiveness when administered with standard management for acute watery diarrhea.
- Study Design and Conduct
This is a randomized, open-label clinical trial conducted in the Children Emergency and Outpatient Department of Paediatric Medicine Unit-II, King Edward Medical University / Mayo Hospital, Lahore, Pakistan.
The study plans to include 88 children, with 44 participants allocated to each treatment group. Participants will be selected using non-probability convenient sampling from children presenting to the study setting who meet the protocol-defined selection criteria. After assessment for eligibility and obtaining written informed consent from a parent or guardian, participants will be allocated to one of the two groups using a lottery method.
The study is open-label, meaning that treatment allocation is not blinded to the participants' caregivers or the study team. Both groups will receive the same general standard management for diarrhea, including oral rehydration therapy, zinc supplementation, and dietary advice. This approach allows the daily frequency of diarrhea to be compared between the two probiotic treatment groups under the same clinical setting and observation period.
- Clinical Assessment and Data Collection
At enrollment, a clinical assessment will be performed, and relevant demographic and clinical information will be recorded on the study proforma. This includes age, sex, weight, vital signs, the onset of diarrhea, and the reported frequency of diarrhea during the preceding 24 hours. Clinical assessment will also establish whether the child meets the protocol's definition of acute watery diarrhea with some dehydration.
During the study period, the frequency of diarrhea episodes will be documented daily. Participants will be followed for three days after admission, and the recorded information will be used to compare the two groups. The study will assess the daily stool frequency observed during follow-up rather than assume that one probiotic is more effective than the other.
- Data Analysis and Interpretation
Study data will be entered and analyzed using Statistical Package for the Social Sciences (SPSS), version 26. Quantitative variables, including age, weight, and stool frequency, will be summarized using means and standard deviations. The independent-samples t-test will be used for comparisons of quantitative variables as specified in the study protocol. Qualitative variables, including sex, dehydration status, and nutritional status, will be summarized as frequencies and percentages and compared using the chi-square test. A p-value of less than 0.05 will be considered statistically significant.
The findings will be interpreted by comparing the recorded diarrhea frequency between the two treatment groups. The results may help inform clinical decision-making regarding the choice of probiotic as an adjunct to standard treatment in children with acute watery diarrhea. The study is intended to provide evidence from a local pediatric clinical setting; its findings will be interpreted in the context of its sample size, study design, and follow-up period.
- Conditions
- Acute Watery Diarrhea, Acute Watery Diarrhoea, Diarrhea
- Being tested
- Saccharomyces boulardii CNCM I-745, Bacillus clausii (O/C, SIN, N/R, T)
- Keywords
- Acute watery diarrhea, Saccharomyces boulardii CNCM I-745, Bacillus clausii
- Medical subject headings
- Diarrhea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Saccharomyces boulardii CNCM I-745Drug
Also called Enflor
Probiotic yeast preparation containing Saccharomyces boulardii CNCM I-745, administered orally at a daily dose of 10 billion colony-forming units (CFU) for 3 days.
Bacillus clausii (O/C, SIN, N/R, T)Drug
Also called Enterogermina
Four-strain probiotic preparation containing Bacillus clausii strains O/C, SIN, N/R, and T, administered orally at a daily dose of 4 billion colony-forming units (CFU) for 3 days.
| Study group | Role | What they receive |
|---|---|---|
| Saccharomyces boulardii CNCM I-745 | Experimental | Participants assigned to this arm will receive Saccharomyces boulardii CNCM I-745 at a daily dose of 10 billion CFU (1 × 10¹⁰ CFU/day) for 3 days. Standard management, including oral rehydration solution (ORS), zinc supplementation, and dietary advice, will also be provided. Receives: Drug: Saccharomyces boulardii CNCM I-745 |
| Multi-strain Bacillus clausii (O/C, SIN, N/R, and T) | Experimental | Participants assigned to this arm will receive multi-strain Bacillus clausii (O/C, SIN, N/R, and T) at a daily dose of 4 billion CFU (4 × 10⁹ CFU/day) for 3 days. Standard management, including oral rehydration solution (ORS), zinc supplementation, and dietary advice, will also be provided. Receives: Drug: Bacillus clausii (O/C, SIN, N/R, T) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Daily frequency of diarrhea episodes
Number of diarrhea episodes per day, recorded daily for 3 days after admission in children aged 6-24 months receiving either Saccharomyces boulardii CNCM I-745 or multi-strain Bacillus clausii, alongside standard treatment for diarrhea.
Measured: Day 1 through Day 3 after admission (3 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study startNov 2026 (estimated)
- Primary completionFeb 2027 (estimated)
- Study completionFeb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Acute Watery DiarrheaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a two-arm, parallel-group, randomized, open-label clinical trial involving 88 children aged 6-24 months with acute watery diarrhea and some dehydration. Participants will be allocated by lottery method into two groups of 44 children each. Group A will receive Saccharomyces boulardii CNCM I-745 at 10 billion CFU/day for 3 days, while Group B will receive multi-strain Bacillus clausii (O/C, SIN, N/R, T) at 4 billion CFU/day for 3 days. Both groups will receive oral rehydration solution (ORS), zinc supplementation, and dietary advice. Diarrhea frequency will be recorded daily during the 3-day follow-up.
- Masking
- None (open label)
- Enrolment
- 88 participants (estimated)
Sponsor and investigators
- Lead sponsor
- King Edward Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dr. Aniqua Tahir, MBBS, MD Paediatrics, Principal investigator, King Edward Medical University / Mayo Hospital Lahore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07921836
- Sponsor's protocol ID
- aniquatahir596
- Status last verified
- Nov 2026
- First submitted
- 29 Oct 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared with other researchers because the study involves young children and the research team intends to protect participant confidentiality and privacy. The data will be used for the purposes of the planned research and reporting of study results in aggregate form.
Publications
Fu H, Li J, Xu X, Xia C, Pan Y. Effectiveness and Safety of Saccharomyces Boulardii for the Treatment of Acute Gastroenteritis in the Pediatric Population: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Comput Math Methods Med. 2022 Sep 20;2022:6234858. doi: 10.1155/2022/6234858. eCollection 2022.
PubMed 36176742Altcheh J, Carosella MV, Ceballos A, D'Andrea U, Jofre SM, Marotta C, Mugeri D, Sabbaj L, Soto A, Josse C, Montestruc F, McFarland LV. Randomized, direct comparison study of Saccharomyces boulardii CNCM I-745 versus multi-strained Bacillus clausii probiotics for the treatment of pediatric acute gastroenteritis. Medicine (Baltimore). 2022 Sep 9;101(36):e30500. doi: 10.1097/MD.0000000000030500.
PubMed 36086703
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Effectiveness of Saccharomyces Boulardii CNCM I-745 and Multi-Strain Bacillus Clausii in Reducing the Frequency of Acute Watery Diarrhea in Children Aged 6 to 24 Months
- ClinicalTrials.gov ID
- NCT07921836
- Acronym / sponsor ID
- aniquatahir596
- Conditions
- Acute Watery Diarrhea, Acute Watery Diarrhoea, Diarrhea
- Keywords
- Acute watery diarrhea, Saccharomyces boulardii CNCM I-745, Bacillus clausii
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 88 participants (estimated)
- Lead sponsor
- King Edward Medical UniversityUniversity, hospital or other
- Study start
- Nov 2026 (estimated)
- Primary completion
- Feb 2027 (estimated)
- Study completion
- Feb 2027 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Clinical Trial Summary
The goal of this clinical trial is to compare the effectiveness of Saccharomyces boulardii CNCM I-745 and multi-strain Bacillus clausii in reducing the frequency of acute watery diarrhea in children aged 6 to 24 months. The main question it aims to answer is:
- Which probiotic is more effective in reducing the daily frequency of acute watery diarrhea in children?
Researchers will compare Saccharomyces boulardii CNCM I-745 with a four-strain mixture of Bacillus clausii (O/C, SIN, N/R, T) to determine which is more effective in reducing diarrhea frequency.
Participants will:
- Receive either Saccharomyces boulardii CNCM I-745 at a daily dose of 10 billion CFU or multi-strain Bacillus clausii at a daily dose of 4 billion CFU for 3 days.
- Receive standard treatment for diarrhea, including oral rehydration therapy (ORS), zinc supplementation, and dietary advice.
- Be followed for 3 days after admission, with daily recording of the frequency of diarrhea episodes.
Detailed description
- Background and Rationale
Acute watery diarrhea is an important cause of morbidity among children under five years of age, particularly in resource-limited settings. In young children, ongoing fluid loss can result in dehydration and may lead to serious complications if appropriate management is delayed. The mainstay of treatment is oral rehydration therapy (ORS), zinc supplementation, continued breastfeeding, and appropriate dietary management. Probiotics have also been used as adjuncts to standard treatment, with the aim of improving clinical recovery. However, the effectiveness of probiotics may vary according to the specific microorganism and strain used.
Saccharomyces boulardii CNCM I-745 is a yeast probiotic that has been investigated for its role in pediatric acute gastroenteritis. Bacillus clausii is a spore-forming bacterial probiotic, and the four strains O/C, SIN, N/R, and T have also been used in the management of gastrointestinal disorders, including diarrhea in children. Although both preparations have been studied individually, direct comparisons between these probiotic preparations in children with acute watery diarrhea remain limited.
Differences in their biological characteristics and the limited availability of direct comparative evidence provide a rationale for evaluating these two preparations within the same clinical setting and study population. Such a comparison may contribute to a better understanding of their relative effectiveness when used alongside standard treatment.
- Study Purpose
The purpose of this study is to compare the effectiveness of *Saccharomyces boulardii* CNCM I-745 and a four-strain preparation of *Bacillus clausii* (O/C, SIN, N/R, and T) in reducing the daily frequency of acute watery diarrhea in young children.
The study focuses on the change in the frequency of diarrhea episodes during the treatment and observation period. The comparison is intended to determine whether the two probiotic preparations differ in their effectiveness when administered with standard management for acute watery diarrhea.
- Study Design and Conduct
This is a randomized, open-label clinical trial conducted in the Children Emergency and Outpatient Department of Paediatric Medicine Unit-II, King Edward Medical University / Mayo Hospital, Lahore, Pakistan.
The study plans to include 88 children, with 44 participants allocated to each treatment group. Participants will be selected using non-probability convenient sampling from children presenting to the study setting who meet the protocol-defined selection criteria. After assessment for eligibility and obtaining written informed consent from a parent or guardian, participants will be allocated to one of the two groups using a lottery method.
The study is open-label, meaning that treatment allocation is not blinded to the participants' caregivers or the study team. Both groups will receive the same general standard management for diarrhea, including oral rehydration therapy, zinc supplementation, and dietary advice. This approach allows the daily frequency of diarrhea to be compared between the two probiotic treatment groups under the same clinical setting and observation period.
- Clinical Assessment and Data Collection
At enrollment, a clinical assessment will be performed, and relevant demographic and clinical information will be recorded on the study proforma. This includes age, sex, weight, vital signs, the onset of diarrhea, and the reported frequency of diarrhea during the preceding 24 hours. Clinical assessment will also establish whether the child meets the protocol's definition of acute watery diarrhea with some dehydration.
During the study period, the frequency of diarrhea episodes will be documented daily. Participants will be followed for three days after admission, and the recorded information will be used to compare the two groups. The study will assess the daily stool frequency observed during follow-up rather than assume that one probiotic is more effective than the other.
- Data Analysis and Interpretation
Study data will be entered and analyzed using Statistical Package for the Social Sciences (SPSS), version 26. Quantitative variables, including age, weight, and stool frequency, will be summarized using means and standard deviations. The independent-samples t-test will be used for comparisons of quantitative variables as specified in the study protocol. Qualitative variables, including sex, dehydration status, and nutritional status, will be summarized as frequencies and percentages and compared using the chi-square test. A p-value of less than 0.05 will be considered statistically significant.
The findings will be interpreted by comparing the recorded diarrhea frequency between the two treatment groups. The results may help inform clinical decision-making regarding the choice of probiotic as an adjunct to standard treatment in children with acute watery diarrhea. The study is intended to provide evidence from a local pediatric clinical setting; its findings will be interpreted in the context of its sample size, study design, and follow-up period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a two-arm, parallel-group, randomized, open-label clinical trial involving 88 children aged 6-24 months with acute watery diarrhea and some dehydration. Participants will be allocated by lottery method into two groups of 44 children each. Group A will receive Saccharomyces boulardii CNCM I-745 at 10 billion CFU/day for 3 days, while Group B will receive multi-strain Bacillus clausii (O/C, SIN, N/R, T) at 4 billion CFU/day for 3 days. Both groups will receive oral rehydration solution (ORS), zinc supplementation, and dietary advice. Diarrhea frequency will be recorded daily during the 3-day follow-up.
| Arm | Type | Receives |
|---|---|---|
| Saccharomyces boulardii CNCM I-745 | Experimental | Drug: Saccharomyces boulardii CNCM I-745Participants assigned to this arm will receive Saccharomyces boulardii CNCM I-745 at a daily dose of 10 billion CFU (1 × 10¹⁰ CFU/day) for 3 days. Standard management, including oral rehydration solution (ORS), zinc supplementation, and dietary advice, will also be provided. |
| Multi-strain Bacillus clausii (O/C, SIN, N/R, and T) | Experimental | Drug: Bacillus clausii (O/C, SIN, N/R, T)Participants assigned to this arm will receive multi-strain Bacillus clausii (O/C, SIN, N/R, and T) at a daily dose of 4 billion CFU (4 × 10⁹ CFU/day) for 3 days. Standard management, including oral rehydration solution (ORS), zinc supplementation, and dietary advice, will also be provided. |
Who may qualify
- Ages
- 6 to 24 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Children aged 6 to 24 months.
- Children of either sex.
- Children with a clinical diagnosis of acute watery diarrhea, defined as three or more loose/liquid stools per day for less than 14 days, with some dehydration.
- Children able to take oral medication.
Key exclusion criteria (4 listed)
- Children with severe systemic illness, including immunodeficiency, sepsis, or congenital gastrointestinal anomalies.
- Children with severe malnutrition.
- Children who received systemic antibiotics, probiotics, or medications affecting gastrointestinal motility, including laxatives, antiemetics, antisecretory agents, adsorbent medications, or opiates, within 7 days before enrollment.
- Children with a known allergy or hypersensitivity to either study probiotic or any of its formulation components.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Saccharomyces boulardii CNCM I-745Also: EnflorProbiotic yeast preparation containing Saccharomyces boulardii CNCM I-745, administered orally at a daily dose of 10 billion colony-forming units (CFU) for 3 days. | Drug | Saccharomyces boulardii CNCM I-745 |
| Bacillus clausii (O/C, SIN, N/R, T)Also: EnterogerminaFour-strain probiotic preparation containing Bacillus clausii strains O/C, SIN, N/R, and T, administered orally at a daily dose of 4 billion colony-forming units (CFU) for 3 days. | Drug | Multi-strain Bacillus clausii (O/C, SIN, N/R, and T) |
Primary outcome
Daily frequency of diarrhea episodes
Time frame: Day 1 through Day 3 after admission (3 days)
Number of diarrhea episodes per day, recorded daily for 3 days after admission in children aged 6-24 months receiving either Saccharomyces boulardii CNCM I-745 or multi-strain Bacillus clausii, alongside standard treatment for diarrhea.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Background: PubMed 36176742Fu H, Li J, Xu X, Xia C, Pan Y. Effectiveness and Safety of Saccharomyces Boulardii for the Treatment of Acute Gastroenteritis in the Pediatric Population: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Comput Math Methods Med. 2022 Sep 20;2022:6234858. doi: 10.1155/2022/6234858. eCollection 2022.
- Background: PubMed 36086703Altcheh J, Carosella MV, Ceballos A, D'Andrea U, Jofre SM, Marotta C, Mugeri D, Sabbaj L, Soto A, Josse C, Montestruc F, McFarland LV. Randomized, direct comparison study of Saccharomyces boulardii CNCM I-745 versus multi-strained Bacillus clausii probiotics for the treatment of pediatric acute gastroenteritis. Medicine (Baltimore). 2022 Sep 9;101(36):e30500. doi: 10.1097/MD.0000000000030500.
- World Health Organization: Diarrhoeal disease - background information on childhood diarrhoea, dehydration, prevention, and management.Link provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data will not be shared with other researchers because the study involves young children and the research team intends to protect participant confidentiality and privacy. The data will be used for the purposes of the planned research and reporting of study results in aggregate form.
Related trials for Acute Watery Diarrhea
Enrolling by invitation
Hypernatremia Fluid Therapy in Childhood Diarrhoea
Hypernatremia, Acute Watery Diarrhea
Recruiting
Bacillus Clausii Versus Multistrain Probiotics for Acute Watery Diarrhea in Children
Acute Watery Diarrhea
Active, not recruiting
Comparison of Bacillus Clausii and Saccharomyces Boulardii for Acute Diarrhea at Day 3
Acute Watery Diarrhea
Active, not recruiting
Comparison of Low Osmolar ORS and ReSoMal for Treating Acute Watery Diarrhea in Severely Malnourished Children Aged 6 Months to 5 Years
Acute Watery Diarrhea, Severe Acute Malnutrition in Childhood
RecruitingPhase 4
Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct
Diarrhoea;Acute, Diarrhea Travelers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dr. Mimpal Singh Associate Professor, Paediatrics, MBBS, MCPS, MD, DCH, PHD, PGPN contact
Dr. Aniqua Tahir, MBBS, MD Paediatrics principal investigator
King Edward Medical University / Mayo Hospital Lahore
Questions about this trial
What is this clinical trial studying?
A study testing Saccharomyces boulardii CNCM I-745 and Bacillus clausii (O/C, SIN, N/R, T) in people with Acute Watery Diarrhea and Acute Watery Diarrhoea, run by King Edward Medical University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dr. Aniqua Tahir Tahir, MBBS, MD Paediatrics (03454078234, aniqua_tahir@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Daily frequency of diarrhea episodes (time frame: Day 1 through Day 3 after admission (3 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07921836, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.